📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Jubilant Pharmova's Montreal Facility Receives USFDA OAI Classification
Jubilant Pharmova's contract manufacturing facility in Montreal, Canada (CMO Montreal), has received an 'Official Action Indicated' (OAI) classification from the USFDA following an audit conducted in October and November 2025. An OAI status typically implies that the regulator may withhold approvals for new products from the site until issues are resolved. However, the company has already implemented remediation measures and resumed production operations at the facility in Q4'FY26. The company continues to work closely with the USFDA to address the specific audit observations.
Key Highlights
USFDA classifies CMO Montreal facility as Official Action Indicated (OAI) following late 2025 audit
Production operations at the site have successfully resumed in Q4'FY26 after remediation efforts
The facility is a strategic alliance under Jubilant HollisterStier, focusing on sterile injectables and ophthalmics
Jubilant Pharmova is working with the USFDA to resolve all outstanding regulatory observations
💼 Action for Investors
Investors should monitor the timeline for the USFDA to upgrade the facility's status from OAI, as this classification can delay new product launches. While the resumption of production is a positive operational step, the regulatory risk remains until a successful re-inspection or close-out letter is received.
Jubilant Pharmova Q3 Revenue Rises 17% to Rs 2,123 Cr; CDMO Growth Offsets Montreal Shutdown
Jubilant Pharmova reported a solid 17% YoY revenue growth in Q3 FY26, reaching Rs 2,123 crore, driven by a 49% surge in the CDMO Sterile Injectables segment. However, normalized PAT declined by 17% to Rs 86 crore, and EBITDA margins contracted to 14.5% due to a temporary remediation-related shutdown at the Montreal facility. The company's leverage improved with Net Debt/EBITDA falling to 1.3x from 1.5x in the previous quarter. Management expects margin recovery in Q4 as production has resumed at the Montreal site and new capacities ramp up.
Key Highlights
Revenue grew 17% YoY to Rs 2,123 Cr, while 9M FY26 revenue reached Rs 5,990 Cr (up 13%).
CDMO Sterile Injectables revenue jumped 49% YoY to Rs 457 Cr, supported by the new Line 3 in Spokane.
EBITDA margins contracted by 172 bps YoY to 14.5% due to Montreal facility shutdown and remediation costs.
Ruby-Fill installation base grew by 37% in 9M FY26, significantly outpacing the 21% growth in FY25.
Generics business remained profitable for the third consecutive quarter with 13% revenue growth.
💼 Action for Investors
Investors should focus on the margin recovery trajectory in Q4 as the Montreal facility resumes operations and high-margin Radiopharma products scale. The strong top-line growth in CDMO and Radiopharma provides a positive long-term outlook despite temporary operational headwinds.
Jubilant Pharmova Q3 Standalone Net Profit Rises 24.5% YoY to ₹66 Million
Jubilant Pharmova reported a 20% YoY growth in standalone revenue to ₹673 million for the quarter ended December 31, 2025. Profit before tax from continuing operations saw a significant surge of 90% YoY, reaching ₹101 million, primarily driven by a sharp reduction in finance costs. The company successfully completed the slump sale of its API business to its subsidiary, Jubilant Biosys, on September 1, 2025, which is now reflected as discontinued operations. Total net profit for the quarter stood at ₹66 million, up from ₹53 million in the corresponding quarter of the previous year.
Key Highlights
Standalone revenue from operations increased 20% YoY to ₹673 million in Q3 FY26.
Profit before tax from continuing operations surged 90% YoY to ₹101 million.
Finance costs significantly decreased to ₹9 million from ₹33 million in the year-ago period.
The API business transfer was completed for a net asset value of ₹5,956 million on September 1, 2025.
Total comprehensive income for the period stood at ₹67 million versus ₹51 million YoY.
💼 Action for Investors
Investors should view the sharp reduction in finance costs and the restructuring of the API business as positive steps toward operational efficiency. Monitor the consolidated results for a clearer picture of the group's overall growth trajectory post-restructuring.